3B Blackbio Dx Limited (BOM:532067)

India flag India · Delayed Price · Currency is INR
1,206.70
-45.35 (-3.62%)
At close: Mar 9, 2026
-33.05%
Market Cap 10.34B
Revenue (ttm) 1.29B
Net Income (ttm) 574.68M
Shares Out 8.57M
EPS (ttm) 67.66
PE Ratio 17.83
Forward PE n/a
Dividend 4.00 (0.32%)
Ex-Dividend Date Sep 19, 2025
Volume 14,431
Average Volume 11,089
Open 1,200.00
Previous Close 1,252.05
Day's Range 1,171.20 - 1,240.90
52-Week Range 1,151.00 - 2,019.90
Beta 0.32
RSI 30.23
Earnings Date May 26, 2026

About 3B Blackbio Dx

3B Blackbio Dx Limited engages in the design, development, manufacturing, and commercialization of molecular diagnostic solutions for infectious diseases, oncology, human genetics and antimicrobial resistance in India. The company offers qPCR-based and lateral flow assays rapid tests and Next Gen Sequencing -based molecular diagnostic kits for accurate and reliable testing on patient samples under the TRUPCR, TRUNGS, TRURAPID, brand for testing on patient samples to diagnostics labs. It also offers agrochemical products; technical support and t... [Read more]

Industry Agricultural Chemicals
Founded 1972
Employees 85
Stock Exchange Bombay Stock Exchange
Ticker Symbol 532067
Full Company Profile

Financial Performance

In fiscal year 2025, 3B Blackbio Dx's revenue was 964.69 million, an increase of 29.64% compared to the previous year's 744.13 million. Earnings were 476.91 million, an increase of 48.56%.

Financial Statements

News

There is no news available yet.